

Targeted Therapy and Biomarkers for Solid Tumors

Guest Editors:

Dr. Anca Zgură

Department of Oncology-
Radiotherapy, “Carol Davila”
University of Medicine and
Pharmacy, 050474 Bucharest,
Romania

**Prof. Dr. Rodica Maricela
Anghel**

Department of Oncology-
Radiotherapy, “Carol Davila”
University of Medicine and
Pharmacy, 050474 Bucharest,
Romania

Deadline for manuscript
submissions:

20 April 2025

Message from the Guest Editors


Targeted therapy emerged in the late 20th century, revolutionizing cancer treatment by focusing on specific molecular targets associated with cancer growth and progression. The discovery and validation of biomarkers have been pivotal in tailoring these therapies to individual patients.

This Special Issue aims to explore the latest developments in targeted therapies and biomarker research for solid tumors. It seeks to highlight innovative approaches, from molecular mechanisms to clinical applications, that contribute to personalized cancer treatment.

We are interested in research that delves into the discovery of novel biomarkers, mechanisms of resistance to targeted therapies, and the development of new therapeutic agents. Studies that integrate multi-omics data and translational research are particularly encouraged.

We welcome original research articles and comprehensive reviews that address any aspect of targeted therapy and biomarker discovery in solid tumors. Submissions focusing on clinical trials, mechanistic studies, and technological advancements in this field are highly valued.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)